Bi-V AICD Indication Criteria
A patient requires a biventricular AICD (CRT-D) when they meet BOTH cardiac resynchronization therapy (CRT) criteria AND implantable cardioverter-defibrillator (ICD) criteria simultaneously.
Core Requirements for Bi-V AICD
The decision breaks down into two parallel assessments that must both be satisfied:
CRT Component Requirements
Strongest indication (Class I, Level A): 1, 2
- LVEF ≤35%
- Sinus rhythm
- LBBB morphology with QRS ≥150 ms
- NYHA Class II-IV symptoms despite optimal medical therapy
Weaker but reasonable indications (Class IIa): 2
- Non-LBBB pattern with QRS ≥150 ms and NYHA Class III/IV
- LBBB with QRS 120-149 ms and NYHA Class II-IV
- Atrial fibrillation patients meeting CRT criteria if AV nodal ablation or rate control achieves near 100% ventricular pacing
- Anticipated frequent ventricular pacing (>40%) with LVEF ≤35%
ICD Component Requirements
Primary prevention (Class I, Level A): 1
For ischemic cardiomyopathy:
- LVEF ≤35% with NYHA Class II-III, measured ≥40 days post-MI and ≥3 months post-revascularization
- LVEF ≤30% with NYHA Class I, measured ≥40 days post-MI and ≥3 months post-revascularization
For nonischemic cardiomyopathy:
- LVEF ≤35% with NYHA Class II-III, measured ≥3 months after optimization of guideline-directed medical therapy
Secondary prevention (Class I, Level A): 1
- Cardiac arrest survivor due to VF/VT without reversible cause
- Sustained VT with significant structural heart disease
Critical Timing Requirements
The patient must wait appropriate intervals before device consideration 1:
- ≥40 days post-MI (without revascularization)
- ≥3 months post-revascularization (for ischemic patients)
- ≥3 months of optimized medical therapy (for nonischemic patients)
This waiting period allows for potential LVEF recovery with medical therapy alone, avoiding unnecessary device implantation.
Absolute Contraindications
Do NOT implant a Bi-V AICD if: 1
- NYHA Class IV symptoms refractory to therapy without candidacy for transplant or mechanical circulatory support
- Comorbidities limiting life expectancy to <1 year
- QRS <130 ms (unless specific pacing indication exists)
- Non-LBBB pattern with QRS <150 ms in NYHA Class I-II patients
The Decision Algorithm
- Confirm HFrEF: LVEF ≤35% on optimized medical therapy
- Assess timing: Meet appropriate post-MI/revascularization or medical optimization intervals
- Evaluate CRT criteria: QRS duration, morphology, rhythm, and NYHA class
- Evaluate ICD criteria: Ischemic vs. nonischemic etiology, NYHA class, and LVEF threshold
- Exclude contraindications: Life expectancy, refractory Class IV symptoms, comorbidities
- If BOTH CRT and ICD criteria met: Recommend CRT-D (Bi-V AICD) 1, 2
Important Clinical Nuances
The 2026 Canadian guidelines strongly recommend (Class I, Strong) that CRT-defibrillator implantation is indicated for patients who have indications for BOTH CRT and ICD 1. This represents the highest level of evidence supporting combined therapy.
Common pitfall: Implanting CRT-pacemaker instead of CRT-D when ICD criteria are met. The guidelines explicitly state that when both indications exist, the defibrillator platform should be used unless specific clinical factors (goals of care, life expectancy, patient preference) favor pacing-only 1.
QRS morphology matters significantly: LBBB pattern has much stronger evidence than non-LBBB patterns. Non-LBBB requires QRS ≥150 ms for reasonable consideration, whereas LBBB shows benefit at QRS ≥120 ms 2, 3.
Atrial fibrillation is not an absolute contraindication but requires either AV nodal ablation or aggressive rate control to ensure near-complete biventricular capture 2.